Alan Cole, MD
Pain Medicine · Hattiesburg, MSNPI 1629264544
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 412 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations.
Across 412 payments — averaging $15.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$760
- Lilly USA, LLC$737
- Supernus Pharmaceuticals, Inc.$417
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$371
- Lundbeck LLC$360
- plus $2K from 25 others
What the payments were for
- Food & beverage$6,230100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 104 | $1,271 |
| Amgen | 38 | $760 |
| Lilly USA, LLC | 46 | $737 |
| Supernus Pharmaceuticals, Inc. | 40 | $417 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 28 | $371 |
| Lundbeck LLC | 17 | $360 |
| Teva Pharmaceuticals USA, Inc. | 20 | $317 |
| Valinor Pharma, LLC | 18 | $271 |
| Pfizer | 15 | $259 |
| Biohaven Pharmaceutical Holding Company Ltd. | 15 | $213 |
| Biohaven Pharmaceuticals, Inc. | 13 | $207 |
| Upsher-smith Laboratories LLC | 9 | $161 |
| Collegium Pharmaceutical, Inc. | 4 | $113 |
| Abbott | 5 | $107 |
| IBSA Pharma Inc. | 6 | $99 |
| Redhill Biopharma Inc. | 6 | $90 |
| Novartis | 5 | $85 |
| Forte Bio-pharma LLC | 2 | $57 |
| Currax Pharmaceuticals LLC | 3 | $42 |
| AstraZeneca | 3 | $37 |
| Amarin Pharma, Inc. | 2 | $35 |
| Avanir Pharmaceuticals, Inc. | 2 | $32 |
| Biodelivery Sciences International, Inc. | 2 | $31 |
| Shionogi Inc | 2 | $30 |
| Siemens Medical Solutions USA, Inc. | 1 | $23 |
| Boston Scientific | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| United Imaging Healthcare North America LLC | 1 | $18 |
| Assertio Therapeutics, Inc. | 1 | $18 |
| GE HealthCare | 1 | $15 |
| Pernix Therapeutics Holdings, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$125
How this compares
$6,230 in reported general payments places this provider in the 60th percentile of 48 pain medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 745 | $55,465 |
| Oxycodone Hcl | 716 | $18,777 |
| Diclofenac Sodium | 662 | $11,697 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 456 | $10,081 |
| MovantikNaloxegol Oxalate | 14 | $5,604 |
| Fentanyl | 46 | $4,848 |
| Gabapentin | 810 | $4,006 |
| Naloxone Hcl | 34 | $2,983 |
| Omega-3 Acid Ethyl Esters | 50 | $2,543 |
| Celecoxib | 362 | $2,271 |
| Hydromorphone Hcl | 42 | $1,342 |
| Amitriptyline Hcl | 265 | $1,240 |
| Morphine Sulfate ErMorphine Sulfate | 21 | $869 |
| Pregabalin | 76 | $864 |
| Topiramate | 174 | $684 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Redhill Biopharma Inc.Movantik | $90 | $5,60414 claims |
| Upsher-smith Laboratories LLCTopiramate | $161 | $684174 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 48 pain medicine providers in Mississippi.
Other pain medicine in Hattiesburg
- Bretley SitzmanHattiesburg$18K
- Dennis MarceloHattiesburg$10K
- Jonathan RayburnHattiesburg$8K
- Brent BevardHattiesburg$6K
- David McKellarHattiesburg$2K
- Joe LeighHattiesburg$414
- Rayhan TariqLaurel$64K
- Alan TorreyVicksburg$30K
- Landon BurnsFlowood$22K
- Joe CookByram$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.